Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CXCR6 | O00574 | 1/20 | 0.41 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7700917 | 1.00 | DRD4 (0.43) | DRD4HCRTR1HCRTR2SMN1; SMN2HSD17B10 | |
| SCHEMBL6095418 | 0.90 | GRIN2B (0.42) | DRD4HCRTR1HCRTR2SMN1; SMN2HSD17B10 | |
| SCHEMBL6094056 | 0.88 | POLB (0.43) | DRD4HCRTR1HCRTR2SMN1; SMN2HSD17B10 | |
| SCHEMBL13508634 | 0.82 | TBXA2R (0.56) | LMNAALDH1A1KDM4EMAPTADRA1A | |
| SCHEMBL6095517 | 0.81 | KCNH2 (0.48) | DRD4LMNAALDH1A1KDM4EHTT | |
| SCHEMBL6093816 | 0.81 | KCNH2 (0.48) | DRD4LMNAALDH1A1KDM4EHTT | |
| SCHEMBL6097411 | 0.77 | HTT (0.46) | DRD4LMNAALDH1A1KDM4EMAPT | |
| SCHEMBL6094476 | 0.76 | HTT (0.43) | DRD4SMN1; SMN2LMNAALDH1A1CACNA1G | |
| SCHEMBL7238628 | 0.76 | ALDH1A1 (0.47) | DRD4LMNAALDH1A1CACNA1GKDM4E | |
| SCHEMBL6092572 | 0.74 | HTT (0.49) | DRD4LMNAALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030150-B2 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2006-04-18 | — | — | US | claimed |
| US-20030119754-A1 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2003-06-26 | — | — | US | claimed |
| US-20060142365-A1 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2006-06-29 | — | — | US | disclosed |
| US-7030150-B2 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2006-04-18 | — | — | US | disclosed |
| US-20030119754-A1 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142365-A1 | Benzimidazole compounds and antiviral uses thereof | MAVS, ZC3HAV1, TIMM13 | DRD4 1827/4885HCRTR1 3510/4885HCRTR2 3961/4885 |
| US-20030119754-A1 | Benzimidazole compounds and antiviral uses thereof | MAVS, ZC3HAV1, TIMM13 | DRD4 1827/4885HCRTR1 3510/4885HCRTR2 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.